Reuters logo
6 months ago
BRIEF-Pfizer announces top-line results from oral strategy trial of Xeljanz compared to Humira
February 16, 2017 / 1:16 PM / 6 months ago

BRIEF-Pfizer announces top-line results from oral strategy trial of Xeljanz compared to Humira

Feb 16 (Reuters) - Pfizer Inc

* Pfizer announces top-line results from the oral strategy trial of xeljanz (tofacitinib citrate) compared to humira(adalimumab)

* Pfizer Inc says xeljanz 5mg plus mtx met its primary endpoint in demonstrating non-inferiority versus humira plus mtx

* Pfizer Inc says xeljanz 5mg monotherapy did not meet its primary endpoint of non-inferiority versus humira plus mtx or versus xeljanz plus mtx Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below